Albuterol-Budesonide Fixed-Dose Combination Inhaler
The FDA-approved combination of albuterol 180 mcg with budesonide 160 mcg (delivered as two actuations of 90/80 mcg each) is the specific example of a low-dose ICS-SABA combination available in the United States 1.
Product Details
This pressurized metered-dose inhaler (pMDI) was FDA-approved in 2023 specifically for:
- As-needed treatment or prevention of bronchoconstriction
- Reducing the risk of asthma exacerbations in patients ≥18 years old
- Use as a reliever with or without maintenance therapy (but NOT indicated for maintenance therapy alone) 2, 3
Clinical Context and Evidence
The 2020 NAEPP guidelines recommend that patients using SABA more than 2 days per week for symptom relief (not prevention of exercise-induced bronchospasm) generally have inadequate control and require step-up treatment 4. For persistent asthma at Step 2, the preferred approach is daily low-dose ICS plus PRN SABA 4.
The albuterol-budesonide combination addresses a critical gap: when patients rely on SABA rescue therapy during worsening symptoms, SABAs alone do not address the underlying inflammation, leaving patients vulnerable to severe exacerbations 1.
Key Trial Data
The MANDALA trial demonstrated that albuterol-budesonide 180/160 mcg reduced the risk of severe asthma exacerbations by 26% compared to albuterol alone (hazard ratio 0.74,95% CI 0.62-0.89, P=0.001) in patients with uncontrolled moderate-to-severe asthma already on ICS-containing maintenance therapy 1.
Importantly, patients used this combination similarly to albuterol alone (mean 2.6 vs 2.8 inhalations/day), with high daily use (≥8 inhalations/day) being rare, and adverse event rates were comparable between groups 5.
Practical Considerations
- Each dose consists of two actuations (total 180 mcg albuterol/160 mcg budesonide per dose)
- A lower-dose formulation (180/80 mcg) also exists but showed borderline significance (HR 0.84, P=0.052) 1
- The combination works through both genomic and nongenomic anti-inflammatory effects during the "window of opportunity" when asthma control is lost 3
- This represents a paradigm shift: intervening with ICS during acute symptoms rather than relying on SABA alone 3
Common Pitfall to Avoid
Do not confuse this with ICS-formoterol (a long-acting beta-agonist) combinations used in SMART therapy. The albuterol-budesonide combination is specifically an ICS-SABA product for as-needed use, not for single maintenance and reliever therapy (SMART) 2, 3.